Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea)

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers constipation-predominant IBS (IBS-C) and IBS without diarrhea. Limited treatment options are available, and only a few drugs have FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceutical’s Trulance), bicyclic fatty acids (Takeda’s Amitiza and Par’s generic lubiprostone), and sodium/hydrogen exchanger 3 (NHE3) inhibitors (Ardelyx’s Ibsrela). These treatments are only moderately effective. Zelnorm, a 5-HT4 receptor agonist, was relaunched in 2019 for IBS-C in women younger than age 65 but was removed from the market again in 2022 for business-related reasons.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-C (including IBS without diarrhea) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C (including IBS without diarrhea) patients?
• How has Linzess been integrated into the treatment algorithm, and what is its source of business? Do Linzess, Trulance, and the newly launched generic lubiprostone continue to gain patient share?
• What percentage of IBS-C patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
• What percentage of IBS-C patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key drugs covered: Ibsrela, Linzess, Trulance, Amitiza, lubiprostone (generic), SSRIs, SNRIs, tricyclic agents , Anticholinergics

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.